Erratum to: a preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
Erratum to: a preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
复制标题
勘误表：一项关于巴氯芬对酗酒者影响的初步双盲、安慰剂对照随机研究。
DOI：
10.1007/s00213-015-3916-z
复制
发表时间：
2015
影响因子：
3.4
通讯作者：
Kenna,GeorgeA
中科院分区：
文献类型：
--
作者：
Leggio,Lorenzo;Zywiak,WilliamH;Edwards,StevenM;Tidey,JenniferW;Swift,RobertM;Kenna,GeorgeA
报告了Lorenzo Leggio、William H.作者：Steven M.作者：Jennifer W.作者声明：Robert M.斯威夫特和乔治A. Kenna（Psychopharmacology，2015 [Jan]，232 [1]，233-243）。这份手稿的原始版本在文本中包含一个错误。句子“BACL”显著减少了烟酒合用的戒烟天数%（BACL，12.1±2.0 vs. PLA，3.5±2.2（M±SE）; F（1，197.6）= 8.27，p= 0.004;图1a）。“应读”BACL显著增加了烟酒合用的戒断天数%（BACL，12.1±2.0 vs. PLA，3.5±2.2（M±SE）; F（1，197.6）= 8.27，p= 0.004;图1a）。（以下原始文章的摘要出现在记录2015-00017-021）.目前还没有批准的单一治疗酒精和尼古丁双重依赖。这是一项初步的双盲安慰剂对照随机临床研究，30名酒精吸烟者随机接受80 mg/天的巴氯芬或安慰剂。一个亚组（n= 18）参加了酒精线索反应experiments.ResultsBaclofen，与安慰剂相比，显着降低了酒精-烟草共同使用的禁欲天数百分比（p= 0.004）。酒精依赖的严重程度缓和巴氯芬的作用，与更高的严重性组有更大的巴氯芬反应（p< 0.001）。尽管两组的烟酒合用天数百分比都有所下降，但安慰剂组的下降幅度大于巴氯芬组（p< 0.001）。单独对酒精或烟草使用的二次分析表明，共同禁欲天数百分比的增加是由大量饮酒天数和吸烟天数百分比的药物差异驱动的。在线索反应substudy，巴氯芬略有减少酒精的冲动（p= 0.058），并显着减少流涎（p= 0.001），但这些影响是不相关的线索type.ConclusionsThis研究提供了初步证据表明，巴氯芬在治疗酒精吸烟者的可能作用。然而，混合的结果和小样本需要更大的验证性研究。（PsycINFO数据库记录（c）2016阿帕，保留所有权利）
Reports an error in" A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers" by Lorenzo Leggio, William H. Zywiak, Steven M. Edwards, Jennifer W. Tidey, Robert M. Swift and George A. Kenna (Psychopharmacology, 2015 [Jan], Vol 232 [1], 233-243). The original version of this manuscript contained a mistake in the text. The sentence'BACL significantly reduced the% days of abstinence from alcohol-tobacco co-use (BACL, 12.1±2.0 vs. PLA, 3.5±2.2 (M±SE); F (1,197.6)= 8.27, p= 0.004; Fig. 1a).'should read'BACL significantly increased the% days of abstinence from alcohol-tobacco co-use (BACL, 12.1±2.0 vs. PLA, 3.5±2.2 (M±SE); F (1,197.6)= 8.27, p= 0.004; Fig. 1a).'(The following abstract of the original article appeared in record 2015-00017-021).RationaleThere is presently no approved single treatment for dual alcohol and nicotine dependencies.ObjectiveThis pilot study investigated baclofen effects in alcoholic smokers.MethodsThis was a preliminary double-blind placebo-controlled randomized clinical study with 30 alcoholic smokers randomized to baclofen at 80 mg/day or placebo. A subgroup (n= 18) participated in an alcohol cue-reactivity experiment.ResultsBaclofen, compared with placebo, significantly decreased the percent days of abstinence from alcohol-tobacco co-use (p= 0.004). Alcohol dependence severity moderated baclofen effects, with the higher severity group having the greater baclofen response (p< 0.001). Although the percent days of alcohol-tobacco co-use declined in both groups, this decline was greater after placebo than baclofen (p< 0.001). Secondary analyses on alcohol or tobacco use alone suggested that the increase in percent days of co-abstinence was driven by the medication differences on heavy drinking days and on percent days smoking. In the cue-reactivity substudy, baclofen slightly decreased alcohol urge (p= 0.058) and significantly reduced salivation (p= 0.001), but these effects were not related to cue type.ConclusionsThis study provides preliminary evidence suggesting a possible role of baclofen in the treatment of alcoholic smokers. However, the mixed results and the small sample require larger confirmatory studies.(PsycINFO Database Record (c) 2016 APA, all rights reserved)